MedTrace Logo

A Study of LP-128 Capsules in Healthy Subjects

NCT05130567 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2025-04-03

No results posted yet for this study

Summary

A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LP-128 Capsules After Single- and Multiple-Dose in Healthy Subjects

Conditions

Interventions

DRUG

LP-128 capsules

Oral dosing with LP-128 capsules

OTHER

Matching Placebo

Oral dosing with placebo capsules to match LP-128 capsules.

Sponsors & Collaborators

  • Guangzhou Lupeng Pharmaceutical Company LTD.

    lead INDUSTRY

Principal Investigators

  • Chongyuan Xu, MD, PhD · Nanfang Hospital of Nanfang Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-19
Primary Completion
2026-09-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05130567 on ClinicalTrials.gov